Review of HSDD management highlights bremelanotide (PT-141) as a late-stage melanocortin receptor agonist therapy

Hypoactive Sexual Desire Disorder (HSDD) is a common condition that negatively affects the health and quality of life for many women. Despite its impact, a significant number of women do not raise this issue with their physicians, leading to underdiagnosis and undertreatment. Gynecologic care providers are in an ideal position to initiate conversations about sexual health. The evaluation of HSDD is complex, requiring a biopsychosocial approach that considers biological, psychological, social, and contextual factors contributing to a woman's low sexual desire. Current therapeutic options are limited, with only one FDA-approved medication, creating a need for new pharmacological agents with different mechanisms of action.

This paper presents a clinical review and proposes a management algorithm for HSDD. The authors conducted a literature search of the Medline database to identify clinically relevant publications on the diagnosis and management of HSDD in women. The review synthesized this information to provide evidence-based strategies for screening, diagnosis, and treatment that can be efficiently implemented in a clinical setting. The paper discusses office-based counseling, psychotherapy, and pharmacotherapy, including the FDA-approved drug flibanserin, off-label use of drugs like transdermal testosterone and bupropion, and emerging treatments.

The review establishes that HSDD can be screened for effectively with a few brief questions during a standard office visit. A biopsychosocial model is recommended for comprehensive patient evaluation and treatment planning. The primary FDA-approved pharmacotherapy for acquired, generalized HSDD in premenopausal women is flibanserin, which functions as a postsynaptic 5-HT1A agonist and 5-HT2A antagonist to decrease serotonin and increase dopamine and norepinephrine levels. Other off-label pharmacological strategies include transdermal testosterone and bupropion. A key emerging therapy highlighted is bremelanotide, a peptide that acts as a melanocortin receptor agonist.

Bremelanotide is identified as being in late-stage clinical development, positioning it as a near-future therapeutic option for HSDD. The authors conclude that while gynecologists are well-positioned to manage HSDD, the current pharmacotherapy options are limited, underscoring the importance of new agents like bremelanotide entering the clinical landscape.

Written by TitrateLab, separately from the study summarized above.